Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study.

Date publication

mai 2019

Journal

Multiple sclerosis and related disorders

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
Miller AE, Vermersch P, Kappos L, Comi G, Freedman MS, Oh J, de Seze J, Truffinet P, Benamor M, Purvis A, Wolinsky JS,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31195337

Résumé

In the phase 3 TOPIC study, teriflunomide significantly reduced the risk of relapse determining conversion to clinically definite multiple sclerosis (CDMS) in patients with clinically isolated syndrome, versus placebo. We assessed clinical and safety outcomes associated with extended teriflunomide treatment in the TOPIC extension study.

Mots clés

Clinically definite multiple sclerosis, Clinically isolated syndrome, Early multiple sclerosis, Relapse rate, Teriflunomide

Référence

Mult Scler Relat Disord. 2019 May 24;33:131-138